Tarsus Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

TARS Tarsus Pharmaceuticals Inc

PTICW PropTech Investment II Equity Warrant Exp 8th Dec 2027 *W EXP 12/08/2027

TKPHF Takeda Pharmaceutical Co Ltd

O Realty Income Corp

HSTA Hestia Insight Inc

NRG NRG Energy Inc

MACK Merrimack Pharmaceuticals Inc

BMY Bristol-Myers Squibb Co

NDAQ Nasdaq Inc

UL Unilever PLC

Go

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.